These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 7117151)

  • 1. [Platelet release proteins in plasma in peripheral arterial obliterative disease during ticlopidine administration].
    Klingemann HG; Egbring R
    Dtsch Med Wochenschr; 1982 Sep; 107(37):1388-91. PubMed ID: 7117151
    [No Abstract]   [Full Text] [Related]  

  • 2. A double-blind trial of ticlopidine in sickle cell disease.
    Semple MJ; Al-Hasani SF; Kioy P; Savidge GF
    Thromb Haemost; 1984 Jul; 51(3):303-6. PubMed ID: 6388012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of ticlopidine on peripheral obliterating arteriopathy].
    Stiegler H; Hess H; Mietaschk A; Trampisch HJ; Ingrisch H
    Dtsch Med Wochenschr; 1984 Aug; 109(33):1240-3. PubMed ID: 6381015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Control of platelet antiaggregation therapy using an electronic aggregometer on whole blood].
    Arpaia MR; Leonardo G; del Guercio R
    Minerva Cardioangiol; 1986 Apr; 34(4):195-8. PubMed ID: 3725023
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lack of effect of low dose acetylsalicylic acid (100 mg/die) on thrombocyte survival and beta-thromboglobulin (beta-TG) and platelet factor 4 (PF 4) in patients with peripheral arterial occlusive disease].
    Minar E; Ehringer H; Jung M; Koppensteiner R; Stümpflen A; Ahmadi R
    Vasa Suppl; 1989; 27():244-6. PubMed ID: 2533741
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic effect of ticlopidine for ischemic leg ulcers.
    Katsumura T
    Agents Actions Suppl; 1984; 15():167-72. PubMed ID: 6385645
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
    Katsumura T; Mishima Y; Kamiya K; Sakaguchi S; Tanabe T; Sakuma A
    Angiology; 1982 Jun; 33(6):357-67. PubMed ID: 7046521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial.
    Knudsen JB; Kjøller E; Skagen K; Gormsen J
    Thromb Haemost; 1985 Jun; 53(3):332-6. PubMed ID: 3901391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease in Argentina. Design, organization and general characteristics of patients at entry. The EMATAP Group.
    Blanchard JF; Carreras LO
    Nouv Rev Fr Hematol (1978); 1992; 34(2):149-53. PubMed ID: 1502021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ticlopidine of platelet function in men with stable angina pectoris.
    Berglund U; von Schenck H; Wallentin L
    Thromb Haemost; 1985 Dec; 54(4):808-12. PubMed ID: 3911481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind controlled study of the efficacy and pharmacological properties of heparan sulfate in patients with occlusive arterial disease of the lower limbs.
    Strano A; Pinto A; Galati D
    Drugs Exp Clin Res; 1990; 16(10):543-50. PubMed ID: 2151628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
    Nyberg G; Larsson O; Westberg NG; Aurell M; Jagenburg R; Blohmé G
    Clin Nephrol; 1984 Mar; 21(3):184-7. PubMed ID: 6705280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview: clinical experiences with ticlopidine.
    Day HJ
    Agents Actions Suppl; 1984; 15():297-309. PubMed ID: 6385654
    [No Abstract]   [Full Text] [Related]  

  • 14. [Platelet aggregation, erythrocyte filterability and changes of some blood coagulation parameters in subjects with chronic obstructive arteriopathy of the lower limbs].
    Macchione C; Neirotti M; Longo F; Friziero M; Molaschi M; Poli L
    Minerva Cardioangiol; 1983; 31(7-8):433-8. PubMed ID: 6646445
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma beta-thromboglobulin level in thromboembolic diseases: a marker of in-vivo platelet release reaction].
    Modiano A
    G Clin Med; 1980 Sep; 61(9):672-8. PubMed ID: 6162700
    [No Abstract]   [Full Text] [Related]  

  • 16. Overcoming aspirin resistance: increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
    Wong S; Morel-Kopp MC; Chen Q; Appleberg M; Ward CM; Lewis DR
    Thromb Haemost; 2006 Jun; 95(6):1042-3. PubMed ID: 16732389
    [No Abstract]   [Full Text] [Related]  

  • 17. The relationship between plasma levels of the factor VIII complex and platelet release products (beta-thromboglobulin and platelet factor 4) in children with the hemolytic-uremic syndrome.
    Appiani AC; Edefonti A; Bettinelli A; Cossu MM; Paracchini ML; Rossi E
    Clin Nephrol; 1982 Apr; 17(4):195-9. PubMed ID: 6176380
    [No Abstract]   [Full Text] [Related]  

  • 18. [Platelet function, serum lipoproteins and clinical aspects in peripheral arterial occlusive disease].
    Kaliman J
    Acta Med Austriaca Suppl; 1982; 26():1-25. PubMed ID: 6762030
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiplatelet drugs in the management of patients with thrombotic disorders.
    Harker LA
    Semin Thromb Hemost; 1986 Apr; 12(2):134-55. PubMed ID: 3016905
    [No Abstract]   [Full Text] [Related]  

  • 20. An inverse relation between platelet factor 4 in the platelet and in the plasma.
    O'Brien JR; Etherington MD
    Thromb Haemost; 1976 Dec; 36(3):649-51. PubMed ID: 1037162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.